AdobeStock_301945106.jpeg

The Newly Institute is an industry leader in psychedelic research. Early, high quality studies in medical assisted psychotherapy have shown impressive response rates in treating mental health disorders, and yet there are limited places where Canadians can seek treatment.

Alternate Brandmark_Olive.png

PSYCHEDELIC RESEARCH

The best current scientific understanding of psychedelic-assted psychotherapy points to it's effectiveness in dismantling deeply rooted psychological defenses, allowing people to gain insights into, and explore painful or traumatic memories in ways their brains would otherwise not allow.

Alternate Brandmark_Olive.png

REFRAME YOUR UNDERSTANDING

When combined with appropriate preparation, psychotherapy and integration practices, psychedelics represent a powerful tool to help us heal from past traumas and make substantial improvements in our mental health. 

BrainSlice-28.png

TRIAL OF PSILOCYBIN VERSUS ESCITALOPRAM FOR DEPRESSION

New England Journal of Medicine, April 2021

HOW ECSTASY AND PSILOCYBIN ARE SHAKING UP PSYCHIATRY

Nature, January 2021

EFFECTS OF PSILOCYBIN-ASSISTED THERAPY ON MAJOR DEPRESSIVE ORDER 

 JAMA Psychiatry, Nov 2020

THE EFFICACY OF INTRAVENOUS KETAMINE INFUSION FO R TREATMENT RESISTANT DEP

Elsevier, 2020

THE CURRENT STATUS OF PSYCHEDELICS IN PSYCHIATRY.

 JAMA Psychiatry, July 2020

MDMA-ASSISTED THERAPY FOR SEVERE PTSD

Natures Medicine, April 2020

CANMAT RECOMMENDATIONS FOR USE OF RACEMIC KETAMINE FOR MAJOR DEPRESSIVE DISORDERS

Canadian Journal of Psychiatry, January 2020

MDMA-ASSISTED PSYCHOTHERAPY FOR TREATMENT OF PTSD.

Psychopharmacology, September 2019

AdobeStock_211148293.jpeg

RAPID RESOLUTION OF SYMPTOMS

Our unique curriculum is dedicated to not just rapidly resolving the symptoms that led to leaving the workplace, but to rapidly returning to the workplace and living a healthy and meaningful life. Individualized planning begins on the day our clients begin our program. The workplace is known to markedly affect the mental health of employees and can be a protective factor that helps facilitate a positive return-to-work. We are happy to work directly with employers to improve resiliency training or facilitate a more supportive and accommodating environment when needed.

KETAMINE: WHY NOW? AND WHERE DO WE GO FROM HERE?

Brain and Behaviour Foundation, June 2018

PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION.

Scientific Reports, October 2017